Article

Dr. Niteesh Choudhry Discusses Value-Based Insurance Design [Part 1 of 4]

Dr. Niteesh Choudhry, Associate Professor, Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics in Boston, discusses VBID and how looming questions revealed from this study show the model’s importance as well as its need to be better defined.

Dr. Choudhry explains that a key method to better defining VBID is to conduct similar studies within other specialties to learn about outcomes when the model is applied to diseases such as diabetes, hypertension, and hyperlipidemia.

Related Videos
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Raj Chovatiya, MD, PhD, MSCI.
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Erin Weber, MS
Lynae Darbes, PhD
Kenny Cole, MD
Richard Lafayette, MD, FACP, Stanford University Medical Center
Related Content
Rural health sign | Image credit: BJP7images - stock.adobe.com
April 15th 2025

FQHCs Show Low Engagement in Hypertension, Diabetes Trials

Pearl Steinzor
A new review finds federally qualified health centers (FQHCs) are underutilized in hypertension and type 2 diabetes clinical research, despite their potential to improve trial diversity.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com
April 11th 2025

Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS

Mary Caffrey Caspian Oliai, MD, MS Rose McNulty
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Managed Care Cast Logo
February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS
On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Raj Chovatiya, MD, PhD, MSCI
April 9th 2025

Addressing Unmet Needs, Emerging Treatment for Atopic Dermatitis: Raj Chovatiya, MD, PhD

Cameron Santoro Raj Chovatiya, MD, PhD, MSCI
Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.
AJMC
April 7th 2025

The Role of Advanced Technologies in Improving Diabetes Outcomes

David G. Marrero, PhD Christopher G. Parkin, MS Grazia Aleppo, MD Irl B. Hirsch, MD Janet McGill, MD, MA Rodolfo J. Galindo, MD Davida F. Kruger, MSN, APRN-BC, BC-ADM Carol J. Levy, MD, CDE Anders L. Carlson, MD Guillermo E. Umpierrez, MD, CDE
This article reviews underlying barriers to health care access and discusses how a value-based diabetes care model could improve patient outcomes and reduce long-term costs.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo